THURSDAY, DECEMBER 14, 2017

2:30pm-5:30pm            Ocean Lanai Terrace            Registration

5:45pm–6:55pm            Aloha Pavilion            Welcome Reception
Discussion Leader:       Hiroshi Kikuchi

EVENING PLENARY SESSION

7:00pm-7:05pm - Introduction: Robert Langer and Yasuhiko Tabata

7:05pm-7:40pm – Joseph DeSimone
Chancellor’s Eminent Professor of Chemistry, University of North Carolina
Title TBA

7:40pm-8:15pm – Shuji Terai
Professor and Chairman, Division of Gastroenterology & Hepatology, Niigata University
Allogenic stem cell therapy for liver cirrhosis

8:15pm-8:40pm - Refreshment Break

8:40pm-9:15pm – Ian Hunter and Patrick Anquetil
Hatsopoulos Professor in Mechanical Engineering, MIT; Chief Executive Officer & Founder, Portal Instruments
Instrumentation for drug delivery

9:15pm-9:50pm – Noritaka Isogai
Professor in Chief, Department of Plastic & Reconstructive Surgery, Kinki University School of Medicine
Tissue engineering technology of bFGF release for various plastic surgical reconstructions
## FRIDAY, DECEMBER 15, 2017

### MORNING PLENARY SESSION
Discussion Leader: Rami Suzuki

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title/Title Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am-8:35am</td>
<td>David Giljohan, Chief Executive Officer, Exicure, Inc.</td>
<td>Title TBA</td>
</tr>
<tr>
<td>8:35am-9:10am</td>
<td>Joseph Vacanti, John Homans Professor of Surgery, Harvard Medical School</td>
<td>Title TBA</td>
</tr>
<tr>
<td>9:10am-9:45am</td>
<td>Lloyd Johnston, Chief Operating Officer and Senior Vice President, Research and Development, Selecta Biosciences</td>
<td>Tolerogenic nanoparticles for the prevention of anti-drug antibodies</td>
</tr>
<tr>
<td>9:45am-10:10am</td>
<td>Refreshment Break</td>
<td></td>
</tr>
<tr>
<td>10:10am-10:45am</td>
<td>Yoshinobu Takakura, Professor, Department of Biopharmaceutics &amp; Drug Metabolism, Kyoto University</td>
<td>Development of delivery systems for nucleic acid drugs</td>
</tr>
<tr>
<td>10:45am-11:20am</td>
<td>Daniel Heller, Assistant Professor, Memorial Sloan-Kettering Cancer Center</td>
<td>Title TBA</td>
</tr>
<tr>
<td>11:20am-11:55am</td>
<td>Takayuki Aoi, Professor, Department of iPS Cell Applications, Kyoto University</td>
<td>Applications of cell fate engineering</td>
</tr>
</tbody>
</table>

### AFTERNOON UNSCHEDULED

### EVENING PLENARY SESSION
Discussion Leader: Susan Hershenson

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title/Title Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00pm-7:35pm</td>
<td>Purnanand Sarma, President and Chief Executive Officer, Taris Biomedical</td>
<td>Unlocking epithelial biology using drug delivery</td>
</tr>
<tr>
<td>7:35pm-8:10pm</td>
<td>Hideki Hasegawa, Head, Department of Pathology, National Institute of Infectious Diseases</td>
<td>Mucosal vaccine and impact of secretory IgA antibody for influenza virus infection</td>
</tr>
<tr>
<td>8:10pm-8:35pm</td>
<td>Refreshment Break</td>
<td></td>
</tr>
<tr>
<td>8:35pm-9:10pm</td>
<td>Mano Manoharan, Senior Vice President, Innovation Chemistry, Alnylam Pharmaceuticals</td>
<td>Title TBA</td>
</tr>
<tr>
<td>9:10pm-9:45pm</td>
<td>Yoshinobu Baba, Professor, Department of Biomolecular Engineering, Nagoya University</td>
<td>Nanobiodevices for ultrafast DNA sequencing, cancer theranostics and iPS cell-based regenerative medicine</td>
</tr>
</tbody>
</table>
SATURDAY, DECEMBER 16, 2017

MORNING PLENARY SESSION

Discussion Leader: Nicholas Peppas

8:00am-8:35am – Yoshitaka Ito
Senior Researcher, Drug Delivery, Astellas Pharma Inc.
Employment of carbon dioxide gas in designing orally disintegrating tablets

8:35am-9:10am – Jessica Ballinger; Ray Knox
Vice President, Strategic Alliances, Lyndra, Inc.; Senior Vice President of Manufacturing, Lyndra, Inc.
Lyndra: Once weekly extended release capsule

9:10am-9:45am – Drew Fromkin
Chief Executive Officer, Tarveda Therapeutics
Title TBA

9:45am-10:10am – Refreshment Break

10:10am-10:45am – Christine Bunt
CEO and Chairman of the BOD, Verseau Therapeutics
Title TBA

10:45am-11:20am – Michael Sefton
University Professor, University of Toronto
Preparing the ground for endogenous repair

11:20am-11:55am – Willem Mulder; Zahi Fayad
Professor of Radiology, Icahn School of Medicine at Mt. Sinai; Professor of Radiology and Medicine (Cardiology), Icahn School of Medicine at Mt. Sinai
The immune system as a target for treating complex cardiovascular disease

AFTERNOON UNSCHEDULED

Discussion Leader: Howard Rosen

EVENING SESSION – POSTER SESSION 1

7:30pm – 9:30pm Oral Presentation of Posters - Selected from Poster Session #1

Refreshment Break: 8:30pm

Session ends at approximately 10:00 pm
SUNDAY, DECEMBER 17, 2017

MORNING PLENARY SESSION
Discussion Leader: Amir Nashat

8:00am-8:35am – Christopher Loose
Chief Scientific Officer, Frequency Therapeutics
Title TBA

8:35am-9:10am – Devyn Smith
Chief Strategy Officer and Head of Operations, Sigilon Therapeutics
Immune privileged living therapeutics

9:10am-9:45am – Francis Szoka
Professor of Bioengineering, Therapeutic Sciences and Pharmaceutical Chemistry, University of California – San Francisco
Innovation that expands the range of drugs suitable for liposome drug delivery

9:45am-10:10am - Refreshment Break

10:10am-10:45am – Hiroshi Kikuchi
Executive Director, Tsukuba Research Laboratories, Eisai Co., Ltd.
The past, the present and the future: DDS medicines from the viewpoint of industry

10:45am-11:20am – Chad Mirkin
Rathman Professor of Chemistry, Northwestern University
Title TBA

11:20am-11:55am – R. Loch Macdonald
Professor of Surgery, University of Toronto; Chief Scientific Officer, Edge Therapeutics
Some clinical applications of sustained release of drugs in neurosurgery

AFTERNOON UNSCHEDULED

EVENING PLENARY SESSION
Discussion Leader: Rodney Pearlman

7:00pm-7:35pm – Scott Tarriff
President & Chief Executive Officer, Eagle Pharmaceuticals
Title TBA

7:35pm-8:10pm – Bill Welch
Chief Technology Officer, Phillips-Medisize Corporation
Title TBA

8:10pm-8:35pm – Refreshment Break

8:35pm-9:10pm – Henry Brem
Professor and Director, Dept. of Neurosurgery, Johns Hopkins University
New understanding of brain tumor therapies

9:10pm-9:45pm – Yuichi Sugiyama
Head, Sugiyama Laboratory, RIKEN Innovation Center
Targeting of small molecules to liver by transporters: Statins and anti-HCV drugs as examples
MORNING PLENARY SESSION

Discussion Leader: Chae-Ok Yun

8:00am-8:35am — Christian Kastrup
Assistant Professor, University of British Columbia
Title TBA

8:35am-9:10am – Hirohide Saito
Professor, Department of Life Sciences Frontiers, Kyoto University
Synthetic RNA/RNP technologies to program mammalian cell-fate

9:10am-9:45am – Lucas Chase
Director, Ocular Cell Therapy, Cellular Dynamics International – A Fujifilm Company
Development of Human iPSC-derived ocular therapies

9:45am-10:10am – Refreshment Break

10:10am-10:45am – John Patton
Dance Pharmaceuticals, Inc.
Title TBA

AFTERNOON UNSCHEDULED

EVENING SESSION – POSTER SESSION 2

Discussion Leader: Bruce Zetter

7:30pm Oral Presentation of Posters - Selected from Poster Session #2

Refreshment Break: 8:30pm

Session ends at approximately 10:00 pm

THANK YOU FOR PARTICIPATING -
WE HOPE TO SEE YOU AGAIN AT
THE 15TH SYMPOSIUM IN 2019